Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
about
Pain related to cancer treatments and diagnostic procedures: a no man's land?Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.Adjuvant therapy use among Appalachian breast cancer survivorsA humanized pattern of aromatase expression is associated with mammary hyperplasia in mice.Gender-specific differential expression of exosomal miRNA in synovial fluid of patients with osteoarthritis.Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.Risk of fracture and the concomitant use of bisphosphonates with osteoporosis-inducing medications.Lifestyle interventions for cardiovascular risk reduction in women with breast cancer.Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis.Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.Uterine leiomyosarcoma manifesting as a tricuspid valve mass.Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.Symptoms of endocrine treatment and outcome in the BIG 1-98 study.Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review.A prospective model of care for breast cancer rehabilitation: bone health and arthralgias.Pharmacogenomics of osteoporosis: a pathway approach.Pharmacogenomics of third-generation aromatase inhibitors.Acupuncture for Aromatase Inhibitor-Induced Arthralgia: A Systematic Review.Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy.The association between pre-treatment occupational skill level and mood and symptom burden in early-stage, postmenopausal breast cancer survivors during the first year of anastrozole therapy.Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.Does Aromatase Inhibitors Cause Sjogren's Syndrome and Polyneuropathy?Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study.Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors.Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.Efficacy of Complementary Therapies in the Quality of Life of Breast Cancer Survivors.Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy.Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study.Endocrine Treatment-Related Symptoms and Patient Outcomes in Breast Cancer: A Meta-Analysis.Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event
P2860
Q27026749-A6D54E86-91D7-4719-9B34-36A52B28A5E5Q30275906-07931826-FE40-44EA-8AF1-33E7DBC53795Q30279083-88A83E8F-B541-4B35-8597-2B49D3BA00EEQ30419027-77685C82-B07A-49D3-8EAD-7B279883DDE2Q33700665-8FDE73B8-B501-4009-9854-6A1E98750E82Q33927985-CFFA9739-C486-45C6-8560-2A9AE0DFB8FEQ34462037-B03CCB7E-80F0-4708-B837-EFD7543D7F57Q35878469-ED61F02A-9640-491F-855C-1FC821830B5CQ36282120-98C0ACC7-1921-4A12-AEEA-5890E793BA80Q36728379-FD763294-B377-41F2-BF94-2D1179A7DC66Q36744460-D3B223D4-6DD1-4ADC-AC8D-0F471A2815F0Q37449530-0C3EFC6E-D675-4F89-B4BC-44C27CD0C080Q37553885-C93BBAF7-A858-4FB1-9367-91EFB9B4997BQ37669293-767ABCD9-5A33-42C2-B9A7-208AB98B7213Q38001377-D7A2428E-4E6E-42CF-8A62-11BE1B3310B5Q38010749-B0FD9077-E5A2-4208-9249-6B561A2064F1Q38010777-94AADDBF-FC1E-4C44-A5DE-1621CC36ABB7Q38556576-4D3A6FD5-03CB-443E-9873-73BDCE2BFC59Q39190544-2184385F-1647-441B-ABC4-5AB676F31B16Q41983968-7851D532-7BB4-498A-B9FD-FB6AC0F6A0C5Q44346721-500E28DE-BE06-4DD1-BC40-B23D9CF86E76Q47114383-8348E2BF-392F-4AF7-A130-41C643CE8038Q47201467-8D72AEAE-15B7-4105-9C53-7B805AD6A7FFQ48068071-8FCA1414-067C-4E4D-AD1B-B269BB7583A3Q48119309-E55EDB2B-0211-481F-B1F1-334149AFA0A8Q49627304-3FB3F84E-1B1D-413E-BA7D-6228981F1731Q50933929-C57DD26F-36BB-4B4D-AB32-50BBC6F95142Q54351835-8A818E99-CE6B-4944-A986-EAC24A459832Q54966058-927ECD27-C23A-43DF-A72C-162A483C7DCBQ58768119-CD67B45A-8904-4DF5-879A-DC11A6F409E4
P2860
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Aromatase inhibitor-associated ...... and strategies for management
@ast
Aromatase inhibitor-associated ...... and strategies for management
@en
type
label
Aromatase inhibitor-associated ...... and strategies for management
@ast
Aromatase inhibitor-associated ...... and strategies for management
@en
prefLabel
Aromatase inhibitor-associated ...... and strategies for management
@ast
Aromatase inhibitor-associated ...... and strategies for management
@en
P2860
P921
P356
P1476
Aromatase inhibitor-associated ...... and strategies for management
@en
P2093
Stéphanie Gaillard
P2860
P2888
P356
10.1186/BCR2818
P577
2011-03-14T00:00:00Z
P5875
P6179
1036206953